SCHEMBL29323635

SCHEMBL29323635

O=C(c1ccccc1)C1C(c2ccccc2)C1[N+](=O)[O-]

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 1/20 0.42
▸ MAPT P10636 5/20 0.41
▸ MEN1 O00255 4/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ ALDH1A1 P00352 4/20 0.41
▸ HTT P42858 3/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ LMNA P02545 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ HDAC4 P56524 2/20 0.40
▸ HDAC3 O15379 1/20 0.40
▸ HDAC7 Q8WUI4 1/20 0.40
▸ HDAC8 Q9BY41 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40
▸ HDAC9 Q9UKV0 1/20 0.40
▸ HDAC5 Q9UQL6 1/20 0.40
▸ CES2 O00748 1/20 0.39
▸ CES1 P23141 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6982850 0.78 HDAC4 (0.55) EPHX1MAPTALDH1A1HTTHDAC4
SCHEMBL22570573 0.78 HDAC4 (0.55) EPHX1MAPTALDH1A1HTTHDAC4
SCHEMBL22553016 0.68 TSHR (0.54) EPHX1MEN1KMT2AHTTMAPK1
SCHEMBL22570523 0.68 TSHR (0.54) EPHX1MEN1KMT2AHTTMAPK1
SCHEMBL22570569 0.68 TSHR (0.54) EPHX1MEN1KMT2AHTTMAPK1
SCHEMBL22570599 0.68 TSHR (0.54) EPHX1MEN1KMT2AHTTMAPK1
SCHEMBL22570596 0.68 TSHR (0.54) EPHX1MEN1KMT2AHTTMAPK1
SCHEMBL22570521 0.68 TSHR (0.54) EPHX1MEN1KMT2AHTTMAPK1
SCHEMBL22570576 0.68 TSHR (0.54) EPHX1MEN1KMT2AHTTMAPK1
SCHEMBL5971693 0.68 EPHX1 (0.43) EPHX1MAPTHTTHDAC4HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238264-A1 INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF DISARM THERAPEUTICS, INC. 2024-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238264-A1 INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF SARM1, NADK, NNMT EPHX1 2580/4885MAPT 242/4885MEN1 3371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback